American Journal of Psychiatry
- Volume 178
- Number 2
- February 2021
EDITOR’S NOTE
Editorials
Commentary
Clinical Case Conference
Reviews and Overviews
Publication date: 10 November 2020
Pages136–155Adolescence is a peak time for the onset of psychiatric disorders, with anxiety disorders being the most common and affecting as many as 30% of youths. A core feature of anxiety disorders is difficulty regulating fear, with evidence suggesting deficits in ...
https://doi.org/10.1176/appi.ajp.2020.20020232Articles
Publication date: 15 October 2020
Pages156–164Objective: Although anxiety can be an adaptive response to unpredictable threats, pathological anxiety disorders occur when symptoms adversely affect daily life. Whether or not adaptive and pathological anxiety share mechanisms remains unknown, but if they ...
https://doi.org/10.1176/appi.ajp.2020.19111153Publication date: 25 September 2020
Pages165–173Objective: Dissociative experiences commonly occur in response to trauma, and while their presence strongly affects treatment approaches in posttraumatic spectrum disorders, their etiology remains poorly understood and their phenomenology incompletely ...
https://doi.org/10.1176/appi.ajp.2020.19060647Publication date: 30 June 2020
Pages174–182Objective: Neuroimaging research has revealed that structural brain alterations are common across broad diagnostic families of disorders rather than specific to a single psychiatric disorder. Such overlap in the structural brain correlates of mental ...
https://doi.org/10.1176/appi.ajp.2020.19090934Publication date: 11 September 2020
Pages183–192Objective: In the context of the importance of elucidating the determinants of the initial, newborn setting of telomere length (TL), it is increasingly evident that maternal stress and stress-related processes during pregnancy play a major role. Although ...
https://doi.org/10.1176/appi.ajp.2020.19101003Publication date: 05 January 2021
Pages193–202Objective: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine ...
https://doi.org/10.1176/appi.ajp.2020.20050596Letters to the Editor
Correction
Past Issues
View Issues Archive
Vol. 181 | No. 12
Vol. 181 | No. 11
Vol. 181 | No. 10
